Agreements

* On September 16, 2013, ImmunoGenes has announced the initiation of a collaboration between ImmunoGenes and Massachusetts General Hospital (MGH) focused on the development of antibodies. Under the collaboration, MGH will identify key targets in hematological cancers, and ImmunoGenes will generate antibodies against those targets using its proprietary FcRn-overexpressing transgenic (tg) mice. MGH, including scientists David Sykes, MD, PhD, and David Scadden, MD, has previously published extensively on hematological diseases, including acute myeloid leukemia (AML). Similarly, ImmunoGenes has previously published at length on the ability of its FcRn tg mice to generate antibodies against difficult targets as a result of their improved antigen presentation and generation of increased antibody diversity.